insights_auto
Why is 2X1 up 2.86%?
Dive Deeperchevron_right
2X1:ETR
Abivax SA
€79.00
arrow_upward
+2.86%(+2.20) 1D
Oct 9, 5:35:37 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 2X1...
Open
€78.95
High
€80.40
Low
€78.95
Mkt. cap
6.81B
Avg. vol.
1.81K
Volume
189.00
52-wk high
€137.40
52-wk low
€60.85
EPS
-€5.20
No. of employees
98
Open
€78.95
High
€80.40
Low
€78.95
Mkt. cap
6.81B
Avg. vol.
1.81K
Volume
189.00
52-wk high
€137.40
52-wk low
€60.85
EPS
-€5.20
No. of employees
98
News stories
From web sources and news partners
TradingView
·
2 days ago
Abivax SA Stock 12‑Month Price Target Cut to $159.06, Implies 79% Upside
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
FoundedDec 4, 2013
Headquarters-
SectorBiotechnology
Websiteabivax.com